The domestic producer of the new coronavirus vaccine had applied for the government’s early approval program to meet the demands for the expected third injections period. The company’s inactivated vaccine is considered to have reduced frequency of developing side effects, compared to mRNA vaccines including Phyzer and Moderna doses. Clinical trial for adults will begin by the end of 2021, before another trial for children between 6 m/o and 17 y/o in the spring of 2022. Source: Asahi / Kumanichi / NHK
Disclaimer: Fukuoka Now posts summaries of Kyushu area news for those who cannot read Japanese. These are mostly summaries of publicly posted news from the Japanese media. Errors might occur during translation, those are ours. Images are sourced separately and are for illustrative purposes only. Use this form to send feedback. Please share links to this page, it helps us.
English language Fukuoka & Kyushu local news summaries are posted here every day.
Or sign up for our free weekly newsletter with all the top stories in one convenient email.
More Kyushu news on Twitter, Instagram, and Facebook
